Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | PPARD | Q03181 | 1/20 | 1.00 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 1.00 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 1.00 |
| ▸ | ZDHHC7 | Q9NXF8 | 2/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10595854 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL11595308 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL9096771 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL817063 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL3954970 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL3954525 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL23829555 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL337934 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL8572016 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL2718855 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10925846-B2 | Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-02-23 | — | — | US | disclosed |
| EP-3443957-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | LIMINAL BIOSCIENCES LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| CN-106999459-B | Phenyl ketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | 里米诺生物科学有限公司 | 2020-07-10 | — | — | CN | disclosed |
| EP-3443957-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2019-02-20 | — | — | EP | disclosed |
| US-20190038580-A1 | PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARAMCEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | Liminal Biosciences Limited (GB) | 2019-02-07 | — | — | US | disclosed |
| EP-2632452-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LTD (GB) | 2018-09-26 | — | — | EP | disclosed |
| EP-2632885-B1 | PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC PHARMA SMT LTD (GB) | 2018-01-03 | — | — | EP | disclosed |
| US-9475750-B2 | Phenylketone carboxylate compounds and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC. (CA) | 2016-10-25 | — | — | US | disclosed |
| US-9439882-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2016-09-13 | — | — | US | disclosed |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC PHARMA SMT LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| US-9114118-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2015-08-25 | — | — | US | disclosed |
| EP-2632885-A1 | PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2013-09-04 | — | — | EP | disclosed |
| EP-2632452-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ProMetic BioSciences Inc. (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225681-A1 | Phenylketone Carboxylate Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-29 | — | — | US | disclosed |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| WO-2012097427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC BIOSCIENCES INC. (CA) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012055014-A1 | PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2012-05-03 | — | — | WO | disclosed |
| US-5852212-A | Process for preparation of optically active α-bromo and α-chlorocarboxylic compounds | ROLIC AG (CH) | 1998-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | DCK, TOP2B, TOP2A | LCK 2232/4885PPARD 1956/4885ZDHHC20 1884/4885 |
| US-10925846-B2 | Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | NCEH1, CTSH, BCKDK | LCK 3962/4885PPARD 1421/4885ZDHHC20 154/4885 |
| US-20130225681-A1 | Phenylketone Carboxylate Compounds and Pharmaceutical Uses Thereof | BCKDK, PDK4, FAH | LCK 2836/4885PPARD 1802/4885ZDHHC20 172/4885 |
| US-20190038580-A1 | PHENYLKETONE CARBOXYLATE COMPOUNDS AND PHARAMCEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | PAH, NCEH1, CCNH | LCK 3990/4885PPARD 1346/4885ZDHHC20 347/4885 |
| US-20150313856-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | DCK, TOP2B, TOP2A | LCK 2232/4885PPARD 1956/4885ZDHHC20 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.